Skip to main content
Premium Trial:

Request an Annual Quote

ACT Genomics Raises $12.5M in Series B Financing Round

NEW YORK (GenomeWeb) – ACT Genomics announced today that it has raised $12.5 million in a Series B financing round.

The Taiwanese company current sells two molecular diagnostic cancer assays including ACTDrug, which uses next-generation sequencing to identify genomic alterations responsible for tumor pathogenesis and determine patient response to treatment; and ACTOnco+, which uses NGS to determine the mutational status of solid tumors and guide treatment selection.

ACT Genomics said that it will use the proceeds of the Series B round to increase capacity to support its expansion in Japan, Taiwan, Singapore, Malaysia, Thailand, and Hong Kong, as well as to bolster commercial channels to drive further global expansion.

The company conducted a Series A round in February 2015, and raised $8 million. Those funds had been earmarked to support further investment in the firm's molecular diagnostic assays and expansions of its sales, marketing, and medical teams.


The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.